title: Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.
abstract: OBJECTIVE
  The aim of this study was to evaluate long term safety and antiviral activity of different doses of emtricitabine given once daily to patients chronically infected with hepatitis B.
  
  
  METHODS
  Eligible patients were randomized in a double-blind, parallel study to evaluate 25, 100 or 200 mg once daily doses of emtricitabine for 48 weeks. Patients were then followed for an additional 48 weeks on open-label 200 mg emtricitabine. Serum HBV DNA, ALT, and hepatitis B serology were measured at regular intervals over the 2 years. Resistance surveillance was performed after 1 and 2 years on viremic samples, i.e. > 4700 copies/mL.
  
  
  RESULTS
  Emtricitabine was well tolerated and produced a dose proportional antiviral response. After 2 years, 53% of the patients had serum HBV DNA < or = 4700 copies/mL, 33% seroconverted to anti-HBe and 85% had normal ALT. Eighteen percent of the patients who had received 200 mg emtricitabine for 2 years developed resistance mutations.
  
  
  CONCLUSIONS
  Emtricitabine was well tolerated and demonstrated a potent antiviral response for up to 2 years in patients with chronic hepatitis B infection. Based on these data, 200 mg emtricitabine once daily was chosen as the optimal dose for future hepatitis B studies.
authors.affiliation: California Pacific Medical Center, San Francisco, CA, USA.
authors.forename: Robert G
authors.initials: RG
authors.lastname: Gish
authors.forename: Huy
authors.initials: H
authors.lastname: Trinh
authors.forename: Nancy
authors.initials: N
authors.lastname: Leung
authors.forename: Francis K L
authors.initials: FK
authors.lastname: Chan
authors.forename: Michael W
authors.initials: MW
authors.lastname: Fried
authors.forename: Teresa L
authors.initials: TL
authors.lastname: Wright
authors.forename: Chia
authors.initials: C
authors.lastname: Wang
authors.forename: Jane
authors.initials: J
authors.lastname: Anderson
authors.forename: Elsa
authors.initials: E
authors.lastname: Mondou
authors.forename: Andrea
authors.initials: A
authors.lastname: Snow
authors.forename: Jeff
authors.initials: J
authors.lastname: Sorbel
authors.forename: Franck
authors.initials: F
authors.lastname: Rousseau
authors.forename: Lawrence
authors.initials: L
authors.lastname: Corey
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D000068679:Emtricitabine; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D003841:Deoxycytidine; D000410:Alanine Transaminase; D000068679:Emtricitabine